THURSDAY, MAY 29, 2008

09:00-10:50

SESSION I: PHARMACOGENETICS
Chairperson: Dr. Dan Goldstaub,
Tiltan Pharma, Israel

Dan Panorama – Golan Hall

09:10-09:35

Pharmacogenetics in Current Use - Some Examples and the Lessons They Teach
Dr. Dan Goldstaub
Tiltan Pharma, Israel

09:35-10:00

Pharmacogenetics and Translation Towards Personalized Medicine in Multiple Sclerosis
Prof. Ariel Miller
Department of Neurology, Carmel Medical Center, Israel

10:00-10:25

The Implementation of Pharmacogenetics in the Pharmaceutical Industry
Dr. Amir Tchelet
Teva Pharmaceutical Industries, Israel

10:25-10:50

Regulation of Pharmacogenetic Trials in Israel
Dr. Zelina Ben-Gershon
Ministry of Health, Israel

10:50-11:20

COFFEE BREAK

11:20-13:00

SESSION II: DRUG SAFETY FROM PHASE I TO SUBMISSION
Chairperson: Dr. Hedva Voliovitch,
Teva Pharmaceutical Industries, Israel

Dan Panorama - Golan Hall

11:20-11:40

The European Risk Management Plan From Clinical Trails to File Submission
Dr. Liat Flaishon
Teva Pharmaceutical Industries, Israel

11:40-12:00

Research & Special Population: People With Disabilities
Prof. Avi Ohry
Reuth Medical Center, Israel

12:20-13:00

The Challenge of Vigilance Reports With Drugs Versus Medical Devices and Combination Products
Dr. Monica Tocchi
Meditrial, Italy

13:00-14:00

LUNCH BREAK

14:00-15:20

SESSION III: INFORMED CONSENT
Chairperson: Prof. Jacques Michel,
Hadassah University Medical Center, Israel

Dan Panorama - Golan Hall

14:00-14:20

Informed Consent - the Legal Perspective
Adv. Baruch Shugol
Shugol, Ketzef, Ehrlich, Kerner & Co., Israel

14:20-14:40

Informed Consent – History, Present And Future - the Investigator's Perspective
Dr. Dorit Eldar
BioForum Applied Knowledge Center, Israel

14:40-15:00

The Research Nurse and the Informed Consent
Shula Rabin
Tel Aviv Sourasky Medical Center, Israel

15:00-15:20

Informed Consent – Ideal, Illusion or Deceit? Ethical Considerations
Prof. Jacques Michel
Hadassah University Medical Center, Israel

15:20-15:40

COFFEE BREAK

15:40-16:00

CONFERENCE CLOSING